See the DrugPatentWatch profile for lurbinectedin

Based on the information available, there is limited data on the use of lurbinectedin in pregnancy, as it is not currently approved for use in pregnant women. Lurbinectedin is a chemotherapeutic agent used to treat certain types of cancer. According to the manufacturer's prescribing information, there are no well-controlled studies in pregnant women, and it is not known if lurbinectedin can harm an unborn baby. Therefore, lurbinectedin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus [1].

Additionally, DrugPatentWatch.com, a website that tracks pharmaceutical patents and drug development, does not have any specific information on the use of lurbinectedin in pregnancy [2].

It is important to note that the use of any medication during pregnancy should be discussed with a healthcare provider, as the potential risks and benefits should be carefully weighed. Pregnant women who have taken lurbinectedin should inform their healthcare provider, as close monitoring of the pregnancy and the newborn may be necessary.

In summary, based on the available information, there are no specific abnormalities associated with lurbinectedin use in pregnancy, however, due to limited data, it should only be used during pregnancy if the potential benefit outweighs the potential risk.

Sources:

1. <https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214433s000lbl.pdf>
2. <https://www.drugpatentwatch.com/drugs/lurbinectedin>